|
EP2211615A4
(en)
*
|
2007-10-22 |
2010-10-13 |
Glaxosmithkline Llc |
PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
|
|
US20100048914A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
|
US8415376B2
(en)
|
2008-05-30 |
2013-04-09 |
Amgen Inc. |
Inhibitors of PI3 kinase
|
|
PT2308877E
(pt)
|
2008-08-05 |
2014-05-02 |
Daiichi Sankyo Co Ltd |
Derivados de imidazopiridin-2-ona
|
|
US8367663B2
(en)
|
2009-01-08 |
2013-02-05 |
Curis, Inc. |
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
|
|
BRPI1008745A2
(pt)
|
2009-02-05 |
2019-09-17 |
Tokai Pharmaceuticals Inc |
pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
|
|
WO2010144909A1
(en)
|
2009-06-12 |
2010-12-16 |
Novartis Ag |
Fused heterocyclic compounds and their uses
|
|
ES2709108T3
(es)
|
2009-08-17 |
2019-04-15 |
Intellikine Llc |
Compuestos heterocíclicos y usos de los mismos
|
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
US20110319405A1
(en)
*
|
2010-06-28 |
2011-12-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
|
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
LT3111938T
(lt)
|
2011-04-01 |
2019-06-25 |
Curis, Inc. |
Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
|
|
WO2013049407A2
(en)
*
|
2011-09-30 |
2013-04-04 |
Kineta, Inc |
Anti-viral compounds
|
|
WO2013071264A1
(en)
*
|
2011-11-11 |
2013-05-16 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
|
AU2012340200B2
(en)
|
2011-11-17 |
2017-10-12 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-Terminal Kinase (JNK)
|
|
WO2013142245A1
(en)
*
|
2012-03-23 |
2013-09-26 |
Memorial Sloan-Kettering Cancer Center |
Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
|
|
MX356278B
(es)
*
|
2012-09-20 |
2018-05-22 |
Novartis Ag |
Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa.
|
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
|
US9073946B2
(en)
*
|
2013-01-15 |
2015-07-07 |
Kineta, Inc. |
Anti-viral compounds
|
|
WO2014158649A1
(en)
*
|
2013-03-13 |
2014-10-02 |
Dow Agrosciences Llc |
Preparation of 1,3-(substituted-diaryl)-1,2,4-triazoles
|
|
US20140275564A1
(en)
*
|
2013-03-13 |
2014-09-18 |
Dow Agrosciences Llc |
Process for the preparation of certain triaryl rhamnose carbamates
|
|
CN105682662A
(zh)
|
2013-03-14 |
2016-06-15 |
马里兰大学巴尔的摩校区 |
雄激素受体减量调节剂及其用途
|
|
BR112016002970A2
(pt)
|
2013-08-12 |
2017-09-12 |
Tokai Pharmaceuticals Inc |
biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
|
|
US9745321B2
(en)
|
2013-09-30 |
2017-08-29 |
Shanghai Yingli Pharmaceutical Co., Ltd |
Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
|
|
EP3057955B1
(en)
|
2013-10-18 |
2018-04-11 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
CA2927920A1
(en)
|
2013-10-18 |
2015-04-23 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
IL284952B
(en)
|
2014-01-13 |
2022-08-01 |
Aurigene Discovery Tech Ltd |
History of bicyclic heterocyclyls as irak4 inhibitors
|
|
US9802960B2
(en)
|
2014-01-14 |
2017-10-31 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
WO2015108881A1
(en)
|
2014-01-14 |
2015-07-23 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US10300070B2
(en)
|
2014-03-27 |
2019-05-28 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
CN105130973B
(zh)
*
|
2014-05-26 |
2018-05-01 |
海南国瑞堂中药制药有限公司 |
5-吡啶基-2-氨基-苯并[d]噁唑衍生物及其制备方法和用途
|
|
AU2015270925A1
(en)
|
2014-06-02 |
2016-12-22 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
|
AU2015371251B2
(en)
|
2014-12-23 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2017044858A2
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
US11116754B2
(en)
|
2015-11-13 |
2021-09-14 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of TOR complex 2 increases immunity against bacterial infection
|
|
US10722484B2
(en)
|
2016-03-09 |
2020-07-28 |
K-Gen, Inc. |
Methods of cancer treatment
|
|
WO2018017435A1
(en)
*
|
2016-07-22 |
2018-01-25 |
Accro Bioscience Inc. |
Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
|
|
CN107641118B
(zh)
*
|
2016-07-22 |
2020-11-06 |
爱科诺生物医药股份有限公司 |
具有细胞坏死抑制活性的化合物及其组合物和应用
|
|
PT3600270T
(pt)
*
|
2017-03-31 |
2023-07-25 |
Aurigene Discovery Tech Ltd |
Compostos e composições para tratar distúrbios hematológicos
|
|
WO2018237370A1
(en)
*
|
2017-06-23 |
2018-12-27 |
Accro Bioscience Inc. |
Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
|
|
AU2018289581C1
(en)
*
|
2017-06-23 |
2025-01-30 |
VelosBio Inc. |
ROR1 antibody immunoconjugates
|
|
CN109111464B
(zh)
*
|
2017-06-23 |
2021-02-26 |
爱科诺生物医药股份有限公司 |
一种具有细胞坏死抑制活性的杂环化合物
|
|
KR102858188B1
(ko)
|
2017-10-02 |
2025-09-11 |
주식회사 퍼스트바이오테라퓨틱스 |
벤조티아졸 화합물 및 신경퇴행성 질환을 치료하기 위한 그의 사용 방법
|
|
EP3801069A4
(en)
|
2018-06-01 |
2022-03-16 |
Cornell University |
MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
|
|
CA3102038A1
(en)
|
2018-06-08 |
2019-12-12 |
Ac Immune Sa |
Novel compounds for diagnosis
|
|
CA3099763A1
(en)
|
2018-06-25 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Taire family kinase inhibitors and uses thereof
|
|
SG11202102343QA
(en)
|
2018-09-11 |
2021-04-29 |
Curis Inc |
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
|
CN109320511A
(zh)
*
|
2018-10-26 |
2019-02-12 |
广安凯特制药有限公司 |
一种高纯度帕博西尼中间体产品及其制备方法
|
|
CA3124422A1
(en)
|
2018-12-28 |
2020-07-02 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
KR102892275B1
(ko)
|
2019-02-22 |
2025-11-27 |
주식회사 퍼스트바이오테라퓨틱스 |
이미다조피리디닐 화합물 및 신경퇴행성 장애의 치료를 위한 그의 용도
|
|
JP7456641B2
(ja)
*
|
2019-03-07 |
2024-03-27 |
ファースト・バイオセラピューティクス・インコーポレイテッド |
Ｐｅｔ放射性トレーサーとしての［１８ｆ］標識ベンゾチアゾール誘導体
|
|
US10385046B1
(en)
|
2019-03-19 |
2019-08-20 |
1ST Biotherapeutics, Inc. |
Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
|
|
JP7604387B2
(ja)
*
|
2019-03-28 |
2024-12-23 |
ファースト・バイオセラピューティクス・インコーポレイテッド |
ベンゾチアゾール化合物の薬学的塩、多形体及びその製造方法
|
|
CN110256466A
(zh)
*
|
2019-07-31 |
2019-09-20 |
昆山迪安医学检验实验室有限公司 |
一种噻唑[5,4-b]-吡啶基生物活性化合物的制备方法及其抗肿瘤活性的检测
|
|
WO2021118924A2
(en)
|
2019-12-12 |
2021-06-17 |
Ting Therapeutics Llc |
Compositions and methods for the prevention and treatment of hearing loss
|
|
US20230234967A1
(en)
*
|
2020-05-28 |
2023-07-27 |
Senda Biosciences, Inc. |
Fused Azole Heterocycles as AHR Antagonists
|
|
EP4200299A4
(en)
*
|
2020-08-21 |
2024-09-25 |
1st Biotherapeutics, Inc. |
COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERS
|
|
WO2022038572A1
(en)
*
|
2020-08-21 |
2022-02-24 |
1ST Biotherapeutics, Inc. |
[ 18f]-labeled imidazopyridine derivatives as pet radiotracer
|
|
CA3193865A1
(en)
*
|
2020-09-28 |
2022-03-31 |
Jinhwa Lee |
Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
|
|
BR112023020669A2
(pt)
|
2021-04-08 |
2023-12-12 |
Curis Inc |
Terapias de combinação para o tratamento de câncer
|
|
WO2023288046A1
(en)
|
2021-07-15 |
2023-01-19 |
President And Fellows Of Harvard College |
Compositions and methods relating to cells with adhered particles
|
|
CZ310416B6
(cs)
*
|
2023-12-15 |
2025-05-28 |
Univerzita Hradec Králové |
1-(3-Chlor-4-hydroxyfenyl)-3-(6-((trifluormethyl)thio)benzo[d]thiazol-2-yl)močovina pro použití pro léčbu rakoviny
|